Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Minocycline for HIV+ Cognitive Impairment in Uganda

28 januari 2011 bijgewerkt door: Johns Hopkins University

Minocycline in the Treatment of HIV-Associated Cognitive Impairment in Uganda

Purpose: The purpose of the study is to assess the safety and effectiveness of minocycline, an antibiotic, in the treatment of Human immunodeficiency virus (HIV)-associated cognitive impairment in Uganda.

Study Design: Treatment, 24-week Randomized, Placebo-Controlled, Double-Blind Phase with Optional 24-week Open Label Phase for Subjects with a cluster of differentiation 4 (CD4) Count in the 251-350 Range

  • Arm 1: Minocycline 100 mg orally every 12 hours (50 subjects)
  • Arm 2: Matching placebo orally every 12 hours (50 subjects)

Primary Objective:

· To examine whether minocycline treatment will improve cognitive performance after 24 weeks compared to baseline

Secondary Objectives:

  • To examine whether minocycline treatment for 24 weeks is safe and well-tolerated in individuals with HIV-associated cognitive impairment
  • To examine whether minocycline treatment for 48 weeks is safe and well-tolerated in individuals with HIV-associated cognitive impairment
  • To examine whether minocycline treatment for 24 weeks improves functional impairment

Studie Overzicht

Toestand

Beëindigd

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

73

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Oeganda
      • Kampala, Oeganda
        • Infecious Diseas Institute

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • HIV infection prior to study entry
  • Naïve to any antiretroviral regimen and ineligible to receive antiretroviral therapy by cluster of differentiation 4 (CD4) criteria in Uganda
  • Negative serum or urine pregnancy test for women of childbearing potential
  • Willingness to use birth control
  • Age 18-65 years
  • AIDS Dementia Scale Stage 0.5 OR 1
  • Impaired cognitive performance as evidenced by an International HIV Dementia Scale (HDS) as defined by the protocol
  • Ability to sit or stand and swallow intact capsules with an 8-ounce glass of water
  • Ability and willingness of subject or legal guardian/ representative to give written informed consent
  • Resident within a 20km radius of Kampala city

Exclusion Criteria:

  • Current cancers other than basal cell carcinoma, in situ carcinoma of the cervix, or Kaposi's sarcoma without evidence of visceral involvement or which does not require systemic chemotherapy
  • Severe premorbid psychiatric illness, including schizophrenia and major depression which, in the in investigator's opinion, is likely to interfere with study compliance
  • Active symptomatic AIDS-defining opportunistic infection within 45 days prior to study entry
  • Confounding neurological disorders as defined in the protocol
  • Central nervous system infections or cancers as defined in the protocol
  • Systemic lupus
  • Thyroid disease diagnosed within 24 weeks prior to entry
  • Breastfeeding
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
  • Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator
  • History of allergy/sensitivity to minocycline or other tetracyclines and their formulations
  • Any other clinically significant condition or laboratory abnormality that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study. This includes an individual found to have an HIV dementia scale stage 3 or 4.
  • Any esophageal or other condition that would interfere with the swallowing of the study medication
  • Use of excluded drugs as defined by the protocol

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Minocycline
Minocycline 100 mg orally every 12 hours
Geneesmiddel: minocycline
100 mg capsule every 12 hours by mouth
Placebo-vergelijker: Placebo
Placebo minocycline capsules every 12 hours
Geneesmiddel: minocycline placebo capsule
1 capsule every 12 hours by mouth

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
24-week Change of Uganda Neuropsychological Test Battery Summary Measure (U NP Sum)
Tijdsspanne: At baseline and week 24
The U NP Sum is defined as the average of z scores for 9 neuropsychological test subcomponents in the neuropsychological test battery (i.e. the average of norm-adjusted ("z") scores for Grooved Pegboard Dominant Hand, Grooved Pegboard Non-dominant Hand, Color Trails 1, Color Trails 2, Symbol Digit, WHO-UCLA Verbal Learning test Trial 5, WHO-UCLA Verbal Learning test delayed recall, Digit Span forward and Digit Span backward). The outcome is defined as U NP Sum at week 24 - U NP Sum at baseline.
At baseline and week 24

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
24-week Change of Memorial Sloan Kettering (MSK) HIV Dementia Stage
Tijdsspanne: At baseline and week 24
The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.
At baseline and week 24
24-week Change of Karnofsky Performance Score
Tijdsspanne: At baseline and week 24
The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.
At baseline and week 24
Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms.
Tijdsspanne: Time of initial Grade ≥ 2 toxicity and/or sign and symptom event up to week 24
The outcome is the time to first Grade ≥ 2 toxicity and/or sign and symptoms from study treatment initiation up to week 24. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.
Time of initial Grade ≥ 2 toxicity and/or sign and symptom event up to week 24
Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms
Tijdsspanne: Time of first Grade ≥ 2 toxicity and/or sign and symptom event up to 48 weeks
The outcome is the time of first Grade ≥ 2 toxicity and/or sign and symptoms from treatment initiation up to 48 weeks. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.
Time of first Grade ≥ 2 toxicity and/or sign and symptom event up to 48 weeks
24-week Change of CD4 Cell Counts
Tijdsspanne: At baseline and week 24
The outcome is defined as CD4 cell count at week 24 - CD4 cell count at baseline. The unit is cells/mm^3.
At baseline and week 24
48-week Change of CD4 Cell Counts
Tijdsspanne: At baseline and week 48
The outcome is defined as CD4 cell count at week 48 - CD4 cell count at baseline. The unit is cells/mm^3.
At baseline and week 48
24-week Change of Instrumental Activities of Daily Living
Tijdsspanne: At baseline and week 24
The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.
At baseline and week 24
24-week Change of HIV RNA Plasma Viral Loads (Log10 Transformed)
Tijdsspanne: At baseline and week 24
The outcome is the HIV RNA plasma viral loads (Log10 transformed) at week 24 - the viral loads (Log10 transformed) at baseline.
At baseline and week 24
24-week Change of Center for Epidemiologic Studies Depression (CES-D) Score
Tijdsspanne: At baseline and week 24

The outcome is the total CES-D score at week 24 - the total CES-D score at baseline.

The total CES-D score is based on 20 CES-D items, such as "I was bothered by things that usually don't bother me" and "I did not feel like eating, my appetite was poor". Patients were asked to answer each item by 4 scales: (1) Rarely, (2) Sometimes, (3) Occasionally, and (4) Most of the time. After 4 negative items were multiplied by -1, the total CES-D score is a simple sum of all items.

The min and Max are 0 and 60, respectively. Higher scores indicate more severe depressive symptoms.
At baseline and week 24

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Johns Hopkins University

Medewerkers

Makerere University

Onderzoekers

  • Hoofdonderzoeker: Ned Sacktor, MD, Johns Hopkins School of Medicine

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 april 2008

Primaire voltooiing (Werkelijk)

1 december 2009

Studie voltooiing (Werkelijk)

1 december 2009

Studieregistratiedata

Eerst ingediend

2 maart 2009

Eerst ingediend dat voldeed aan de QC-criteria

2 maart 2009

Eerst geplaatst (Schatting)

3 maart 2009

Updates van studierecords

Laatste update geplaatst (Schatting)

25 februari 2011

Laatste update ingediend die voldeed aan QC-criteria

28 januari 2011

Laatst geverifieerd

1 januari 2011

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • Uganda minocycline study
  • Grant Number: 5 UO1 NS32228

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op HIV-infecties

Zoek naar vergelijkbare onderzoeken

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

CROs by country

CROs in Macedonia

Voorwaarden

Zeldzame ziekten

Geneesmiddelinterventies

Voedingssupplementen

Sponsor / medewerkers

Locaties

3
Abonneren